| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 52 | 2025 | 303 | 8.890 |
Why?
|
| beta-Lactamases | 28 | 2025 | 94 | 4.280 |
Why?
|
| Anti-Bacterial Agents | 47 | 2025 | 375 | 4.060 |
Why?
|
| Infection Control | 29 | 2024 | 170 | 3.980 |
Why?
|
| Klebsiella pneumoniae | 21 | 2023 | 67 | 3.800 |
Why?
|
| Bacterial Proteins | 27 | 2025 | 85 | 3.430 |
Why?
|
| Chlorhexidine | 21 | 2024 | 64 | 3.150 |
Why?
|
| Klebsiella Infections | 19 | 2023 | 61 | 3.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 21 | 2023 | 120 | 2.880 |
Why?
|
| Enterobacteriaceae Infections | 12 | 2021 | 56 | 2.730 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 18 | 2025 | 73 | 2.680 |
Why?
|
| Intensive Care Units | 28 | 2024 | 261 | 2.600 |
Why?
|
| Anti-Infective Agents, Local | 14 | 2024 | 51 | 2.500 |
Why?
|
| Gram-Positive Bacterial Infections | 20 | 2014 | 55 | 2.380 |
Why?
|
| Vancomycin Resistance | 12 | 2014 | 29 | 2.290 |
Why?
|
| Staphylococcal Infections | 22 | 2023 | 166 | 2.270 |
Why?
|
| Enterococcus | 21 | 2014 | 55 | 2.100 |
Why?
|
| Intraabdominal Infections | 9 | 2025 | 10 | 2.050 |
Why?
|
| Humans | 165 | 2025 | 25900 | 2.020 |
Why?
|
| Carrier State | 19 | 2024 | 60 | 2.010 |
Why?
|
| Enterobacteriaceae | 8 | 2020 | 44 | 1.990 |
Why?
|
| Skin | 14 | 2025 | 126 | 1.820 |
Why?
|
| Bacteremia | 19 | 2019 | 99 | 1.810 |
Why?
|
| Candidiasis | 3 | 2025 | 27 | 1.780 |
Why?
|
| Baths | 11 | 2024 | 31 | 1.740 |
Why?
|
| Enterococcus faecium | 7 | 2020 | 12 | 1.350 |
Why?
|
| Disease Outbreaks | 14 | 2023 | 79 | 1.260 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 5 | 2021 | 20 | 1.210 |
Why?
|
| Carbapenems | 9 | 2023 | 42 | 1.210 |
Why?
|
| Long-Term Care | 9 | 2025 | 58 | 1.210 |
Why?
|
| Female | 76 | 2025 | 14543 | 1.200 |
Why?
|
| Chicago | 29 | 2025 | 906 | 1.190 |
Why?
|
| Drug Resistance, Bacterial | 10 | 2022 | 51 | 1.180 |
Why?
|
| Middle Aged | 55 | 2025 | 8556 | 1.120 |
Why?
|
| Candida | 4 | 2023 | 19 | 1.120 |
Why?
|
| Antimicrobial Stewardship | 5 | 2025 | 18 | 1.120 |
Why?
|
| Mupirocin | 7 | 2023 | 17 | 1.070 |
Why?
|
| Male | 66 | 2025 | 14176 | 1.050 |
Why?
|
| Escherichia coli | 5 | 2023 | 45 | 1.020 |
Why?
|
| Microbial Sensitivity Tests | 23 | 2023 | 85 | 1.010 |
Why?
|
| Genomics | 9 | 2025 | 66 | 1.010 |
Why?
|
| Housekeeping, Hospital | 3 | 2014 | 5 | 0.990 |
Why?
|
| Vancomycin | 14 | 2020 | 51 | 0.970 |
Why?
|
| Hospitals | 19 | 2025 | 162 | 0.950 |
Why?
|
| Delivery of Health Care | 10 | 2024 | 140 | 0.940 |
Why?
|
| Adult | 46 | 2025 | 7517 | 0.910 |
Why?
|
| Aged | 43 | 2025 | 8658 | 0.880 |
Why?
|
| Skin Care | 5 | 2024 | 16 | 0.870 |
Why?
|
| Laboratories, Hospital | 1 | 2024 | 4 | 0.860 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 26 | 0.830 |
Why?
|
| Health Facilities | 5 | 2024 | 25 | 0.830 |
Why?
|
| beta-Lactam Resistance | 4 | 2015 | 13 | 0.820 |
Why?
|
| Population Surveillance | 7 | 2018 | 108 | 0.820 |
Why?
|
| Communicable Diseases | 5 | 2023 | 23 | 0.800 |
Why?
|
| Hospital Administration | 3 | 2021 | 24 | 0.790 |
Why?
|
| Medical Order Entry Systems | 4 | 2025 | 9 | 0.750 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 78 | 0.750 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 82 | 0.750 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2025 | 3 | 0.750 |
Why?
|
| Nursing Homes | 7 | 2025 | 42 | 0.730 |
Why?
|
| Dermatomycoses | 1 | 2021 | 5 | 0.720 |
Why?
|
| Disinfection | 4 | 2019 | 10 | 0.720 |
Why?
|
| Clinical Protocols | 1 | 2021 | 58 | 0.690 |
Why?
|
| United States | 20 | 2024 | 1935 | 0.680 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2019 | 160 | 0.680 |
Why?
|
| Bacteriological Techniques | 3 | 2017 | 15 | 0.670 |
Why?
|
| Betacoronavirus | 2 | 2020 | 67 | 0.670 |
Why?
|
| Culture Media | 5 | 2017 | 30 | 0.670 |
Why?
|
| Health Personnel | 7 | 2023 | 98 | 0.660 |
Why?
|
| Mass Screening | 5 | 2018 | 168 | 0.640 |
Why?
|
| Catheterization, Central Venous | 2 | 2010 | 36 | 0.630 |
Why?
|
| Skilled Nursing Facilities | 5 | 2021 | 31 | 0.630 |
Why?
|
| beta-Lactams | 2 | 2010 | 9 | 0.620 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 13 | 2014 | 31 | 0.610 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 3 | 2010 | 8 | 0.610 |
Why?
|
| Genome, Bacterial | 3 | 2017 | 13 | 0.600 |
Why?
|
| Critical Care | 4 | 2023 | 118 | 0.600 |
Why?
|
| Community-Acquired Infections | 9 | 2020 | 68 | 0.600 |
Why?
|
| Rectum | 9 | 2024 | 48 | 0.580 |
Why?
|
| Equipment Contamination | 4 | 2019 | 25 | 0.570 |
Why?
|
| Escherichia coli Infections | 5 | 2018 | 25 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 21 | 0.560 |
Why?
|
| Child | 16 | 2024 | 1180 | 0.550 |
Why?
|
| Specimen Handling | 5 | 2023 | 41 | 0.530 |
Why?
|
| Sensitivity and Specificity | 8 | 2020 | 450 | 0.520 |
Why?
|
| Urinary Tract Infections | 3 | 2024 | 31 | 0.520 |
Why?
|
| Drug Resistance, Microbial | 14 | 2023 | 66 | 0.490 |
Why?
|
| Staphylococcus aureus | 6 | 2023 | 72 | 0.480 |
Why?
|
| Gram-Positive Bacteria | 2 | 2012 | 13 | 0.470 |
Why?
|
| Virulence Factors | 1 | 2014 | 5 | 0.460 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 6 | 0.450 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 9 | 0.450 |
Why?
|
| Bacterial Load | 3 | 2013 | 13 | 0.440 |
Why?
|
| Hand | 5 | 2008 | 40 | 0.440 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 33 | 0.440 |
Why?
|
| Public Health | 4 | 2024 | 68 | 0.440 |
Why?
|
| Vancomycin-Resistant Enterococci | 3 | 2024 | 12 | 0.440 |
Why?
|
| Gloves, Protective | 4 | 2019 | 15 | 0.440 |
Why?
|
| Anal Canal | 1 | 2014 | 3 | 0.430 |
Why?
|
| Acinetobacter baumannii | 1 | 2014 | 5 | 0.430 |
Why?
|
| Acinetobacter Infections | 1 | 2014 | 6 | 0.430 |
Why?
|
| Respiratory Tract Infections | 3 | 2025 | 25 | 0.420 |
Why?
|
| Pregnancy | 8 | 2024 | 327 | 0.420 |
Why?
|
| Methicillin Resistance | 4 | 2007 | 25 | 0.420 |
Why?
|
| Clostridium Infections | 2 | 2023 | 24 | 0.410 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 4633 | 0.400 |
Why?
|
| Prevalence | 12 | 2020 | 431 | 0.390 |
Why?
|
| Disease Transmission, Infectious | 4 | 2021 | 20 | 0.380 |
Why?
|
| Bacterial Infections | 2 | 2024 | 52 | 0.380 |
Why?
|
| Pandemics | 4 | 2023 | 221 | 0.380 |
Why?
|
| Bacteria | 4 | 2025 | 71 | 0.370 |
Why?
|
| Sepsis | 3 | 2023 | 111 | 0.370 |
Why?
|
| Time Factors | 8 | 2020 | 1376 | 0.360 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2008 | 22 | 0.360 |
Why?
|
| Feces | 2 | 2024 | 100 | 0.350 |
Why?
|
| Risk Factors | 14 | 2021 | 2173 | 0.350 |
Why?
|
| Phylogeny | 4 | 2025 | 49 | 0.350 |
Why?
|
| DNA, Bacterial | 8 | 2019 | 40 | 0.340 |
Why?
|
| Air Microbiology | 2 | 2025 | 5 | 0.340 |
Why?
|
| Hospitalization | 8 | 2025 | 295 | 0.330 |
Why?
|
| Polymerase Chain Reaction | 6 | 2020 | 117 | 0.330 |
Why?
|
| Soft Tissue Infections | 3 | 2025 | 25 | 0.310 |
Why?
|
| Fomites | 1 | 2008 | 3 | 0.310 |
Why?
|
| Decontamination | 1 | 2008 | 10 | 0.300 |
Why?
|
| Environmental Monitoring | 3 | 2025 | 10 | 0.300 |
Why?
|
| Hand Disinfection | 5 | 2019 | 25 | 0.300 |
Why?
|
| Disinfectants | 3 | 2014 | 7 | 0.290 |
Why?
|
| Minisatellite Repeats | 1 | 2008 | 8 | 0.290 |
Why?
|
| Endemic Diseases | 1 | 2008 | 7 | 0.290 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 77 | 0.270 |
Why?
|
| Iodophors | 2 | 2024 | 5 | 0.270 |
Why?
|
| Genes, Bacterial | 2 | 2016 | 4 | 0.270 |
Why?
|
| Case-Control Studies | 8 | 2021 | 567 | 0.270 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 56 | 0.260 |
Why?
|
| Metagenomics | 2 | 2025 | 6 | 0.260 |
Why?
|
| Gram-Negative Bacteria | 4 | 2013 | 23 | 0.260 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 55 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 251 | 0.260 |
Why?
|
| Serratia marcescens | 3 | 2011 | 7 | 0.260 |
Why?
|
| Serratia Infections | 3 | 2011 | 7 | 0.260 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 15 | 0.250 |
Why?
|
| Illinois | 8 | 2021 | 236 | 0.250 |
Why?
|
| Plasmids | 4 | 2023 | 42 | 0.250 |
Why?
|
| Reimbursement, Incentive | 2 | 2024 | 7 | 0.240 |
Why?
|
| Molecular Epidemiology | 7 | 2021 | 28 | 0.240 |
Why?
|
| Genome, Fungal | 1 | 2025 | 4 | 0.240 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 8 | 0.240 |
Why?
|
| Daptomycin | 1 | 2005 | 10 | 0.240 |
Why?
|
| Microbiota | 2 | 2025 | 99 | 0.230 |
Why?
|
| Blood Culture | 1 | 2024 | 1 | 0.230 |
Why?
|
| Cholangitis | 1 | 2024 | 1 | 0.230 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 2 | 0.230 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 3 | 0.230 |
Why?
|
| Universal Precautions | 2 | 2024 | 6 | 0.230 |
Why?
|
| Diverticulitis | 1 | 2024 | 6 | 0.230 |
Why?
|
| Appendicitis | 1 | 2024 | 14 | 0.230 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2018 | 38 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 1994 | 158 | 0.220 |
Why?
|
| Nasal Cavity | 5 | 2014 | 33 | 0.220 |
Why?
|
| Public Health Surveillance | 1 | 2024 | 11 | 0.220 |
Why?
|
| Drug Resistance, Multiple | 2 | 2012 | 12 | 0.210 |
Why?
|
| Pneumonia | 1 | 2024 | 67 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2015 | 124 | 0.210 |
Why?
|
| Patient Discharge | 1 | 2024 | 147 | 0.210 |
Why?
|
| Protective Clothing | 2 | 2019 | 8 | 0.190 |
Why?
|
| Subacute Care | 1 | 2021 | 6 | 0.190 |
Why?
|
| Administration, Intranasal | 4 | 2024 | 28 | 0.190 |
Why?
|
| Infant | 6 | 2021 | 503 | 0.180 |
Why?
|
| Universities | 1 | 2021 | 39 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 17 | 0.180 |
Why?
|
| Mandatory Programs | 1 | 2021 | 2 | 0.180 |
Why?
|
| Federal Government | 1 | 2021 | 3 | 0.180 |
Why?
|
| State Government | 1 | 2021 | 7 | 0.180 |
Why?
|
| Disease Reservoirs | 3 | 2010 | 9 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 6 | 0.180 |
Why?
|
| Local Government | 1 | 2021 | 7 | 0.180 |
Why?
|
| Gammaproteobacteria | 1 | 2021 | 4 | 0.180 |
Why?
|
| Viruses | 1 | 2020 | 6 | 0.180 |
Why?
|
| Students | 1 | 2021 | 47 | 0.170 |
Why?
|
| Drug Contamination | 2 | 2011 | 5 | 0.170 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 5 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 4 | 0.170 |
Why?
|
| Prisons | 2 | 2013 | 8 | 0.170 |
Why?
|
| Models, Theoretical | 1 | 2021 | 80 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 5 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2018 | 3339 | 0.170 |
Why?
|
| Survivors | 1 | 2020 | 69 | 0.170 |
Why?
|
| Fresh Water | 1 | 2020 | 5 | 0.170 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 28 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2021 | 176 | 0.160 |
Why?
|
| Water Microbiology | 2 | 2020 | 10 | 0.160 |
Why?
|
| Critical Illness | 3 | 2018 | 113 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2019 | 14 | 0.160 |
Why?
|
| Comorbidity | 2 | 2019 | 457 | 0.150 |
Why?
|
| Medical Errors | 1 | 2019 | 25 | 0.150 |
Why?
|
| Loiasis | 1 | 1998 | 2 | 0.150 |
Why?
|
| Adolescent | 9 | 2021 | 2070 | 0.150 |
Why?
|
| Eye Infections, Parasitic | 1 | 1998 | 4 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2020 | 6 | 0.150 |
Why?
|
| Environmental Microbiology | 2 | 2017 | 5 | 0.150 |
Why?
|
| Patient Transfer | 2 | 2024 | 25 | 0.150 |
Why?
|
| Disease Notification | 1 | 2018 | 5 | 0.150 |
Why?
|
| Lasers | 1 | 2018 | 15 | 0.150 |
Why?
|
| Conjugation, Genetic | 2 | 1997 | 4 | 0.140 |
Why?
|
| Anthropometry | 1 | 2018 | 30 | 0.140 |
Why?
|
| Bacterial Typing Techniques | 4 | 2011 | 10 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 143 | 0.140 |
Why?
|
| Personnel, Hospital | 2 | 2008 | 15 | 0.140 |
Why?
|
| Glycopeptides | 1 | 1997 | 3 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3342 | 0.130 |
Why?
|
| Thailand | 2 | 2014 | 9 | 0.130 |
Why?
|
| Models, Biological | 2 | 2014 | 285 | 0.130 |
Why?
|
| Teicoplanin | 2 | 1994 | 3 | 0.130 |
Why?
|
| Ciprofloxacin | 3 | 2008 | 11 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2021 | 590 | 0.130 |
Why?
|
| Selection, Genetic | 1 | 2016 | 4 | 0.130 |
Why?
|
| Chromogenic Compounds | 2 | 2013 | 3 | 0.130 |
Why?
|
| Infant, Newborn | 5 | 2021 | 553 | 0.130 |
Why?
|
| Multilocus Sequence Typing | 4 | 2021 | 17 | 0.130 |
Why?
|
| Melioidosis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Burkholderia pseudomallei | 1 | 2015 | 3 | 0.120 |
Why?
|
| Travel | 1 | 2015 | 13 | 0.120 |
Why?
|
| Ofloxacin | 1 | 1995 | 1 | 0.120 |
Why?
|
| Genotype | 3 | 2022 | 335 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 55 | 0.120 |
Why?
|
| Levofloxacin | 1 | 1995 | 3 | 0.120 |
Why?
|
| Markov Chains | 1 | 2015 | 31 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 43 | 0.120 |
Why?
|
| Young Adult | 5 | 2021 | 1929 | 0.120 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2015 | 4 | 0.120 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2015 | 7 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2015 | 22 | 0.120 |
Why?
|
| Soaps | 3 | 2010 | 8 | 0.120 |
Why?
|
| Patient Care | 2 | 2013 | 31 | 0.110 |
Why?
|
| Cost Savings | 1 | 2014 | 31 | 0.110 |
Why?
|
| Tertiary Care Centers | 3 | 2019 | 66 | 0.110 |
Why?
|
| Pharynx | 1 | 2014 | 12 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 16 | 0.110 |
Why?
|
| Acute Disease | 2 | 2024 | 165 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2024 | 553 | 0.110 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 2 | 0.110 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2013 | 2 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 309 | 0.100 |
Why?
|
| Colorimetry | 1 | 2013 | 2 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2019 | 1686 | 0.100 |
Why?
|
| Fungi | 1 | 2013 | 3 | 0.100 |
Why?
|
| Aerosols | 1 | 2013 | 16 | 0.100 |
Why?
|
| Poisson Distribution | 2 | 2010 | 21 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2012 | 1815 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2013 | 96 | 0.100 |
Why?
|
| Biomarkers | 1 | 2015 | 536 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 40 | 0.100 |
Why?
|
| California | 2 | 2024 | 31 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 22 | 0.100 |
Why?
|
| HIV Infections | 2 | 2013 | 475 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 18 | 0.090 |
Why?
|
| Consensus | 2 | 2022 | 91 | 0.090 |
Why?
|
| Hospitals, Teaching | 4 | 2010 | 30 | 0.090 |
Why?
|
| Ventilators, Mechanical | 2 | 2021 | 27 | 0.090 |
Why?
|
| Ecosystem | 2 | 2021 | 6 | 0.090 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2007 | 9 | 0.090 |
Why?
|
| Enterococcus faecalis | 2 | 2002 | 5 | 0.080 |
Why?
|
| Blood | 1 | 2009 | 19 | 0.080 |
Why?
|
| Length of Stay | 3 | 2024 | 307 | 0.080 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 13 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 125 | 0.070 |
Why?
|
| Imipenem | 1 | 2008 | 5 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 2008 | 29 | 0.070 |
Why?
|
| Environment | 1 | 2008 | 39 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2020 | 394 | 0.070 |
Why?
|
| Catheterization | 1 | 2007 | 37 | 0.070 |
Why?
|
| Public Housing | 1 | 2007 | 4 | 0.070 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 11 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2018 | 47 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 14 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2007 | 41 | 0.070 |
Why?
|
| Viral Load | 1 | 2007 | 75 | 0.070 |
Why?
|
| Simplexvirus | 1 | 2006 | 4 | 0.070 |
Why?
|
| Hepatitis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2007 | 52 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 18 | 0.060 |
Why?
|
| Syringes | 3 | 2011 | 6 | 0.060 |
Why?
|
| Colony Count, Microbial | 3 | 2015 | 17 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 113 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 313 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2005 | 18 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 25 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 102 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2025 | 14 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 1083 | 0.060 |
Why?
|
| Ampicillin | 2 | 1995 | 5 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1324 | 0.060 |
Why?
|
| Lumbosacral Region | 1 | 2005 | 57 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 149 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1708 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 830 | 0.060 |
Why?
|
| Ascomycota | 1 | 2004 | 2 | 0.060 |
Why?
|
| Mitosporic Fungi | 1 | 2004 | 3 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1994 | 36 | 0.060 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 13 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2024 | 14 | 0.060 |
Why?
|
| Fungemia | 1 | 2004 | 8 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 847 | 0.060 |
Why?
|
| Mycoses | 1 | 2004 | 19 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2004 | 17 | 0.060 |
Why?
|
| Aminoglycosides | 2 | 2013 | 10 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 2 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2004 | 75 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 31 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 38 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 30 | 0.050 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 53 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 6 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 8 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 46 | 0.050 |
Why?
|
| Workflow | 1 | 2022 | 9 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2024 | 130 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2023 | 71 | 0.050 |
Why?
|
| Gelatinases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Animals | 4 | 2020 | 3504 | 0.050 |
Why?
|
| Travel-Related Illness | 1 | 2021 | 3 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 619 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 8 | 0.040 |
Why?
|
| Georgia | 1 | 2021 | 10 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 18 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 91 | 0.040 |
Why?
|
| Mathematics | 1 | 2000 | 29 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 6 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2005 | 385 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 4 | 0.040 |
Why?
|
| Heparin | 2 | 2011 | 21 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 34 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 28 | 0.040 |
Why?
|
| Cephalosporins | 2 | 1998 | 12 | 0.040 |
Why?
|
| Waste Disposal, Fluid | 1 | 2020 | 4 | 0.040 |
Why?
|
| Escherichia coli Proteins | 1 | 2020 | 8 | 0.040 |
Why?
|
| Sodium Chloride | 2 | 2011 | 34 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 206 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 88 | 0.040 |
Why?
|
| Hygiene | 1 | 2019 | 12 | 0.040 |
Why?
|
| Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 131 | 0.040 |
Why?
|
| Integrons | 1 | 2018 | 4 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 184 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 155 | 0.040 |
Why?
|
| Kenya | 1 | 2018 | 11 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 118 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 1999 | 85 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 95 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 589 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 1997 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1997 | 2 | 0.030 |
Why?
|
| Chromosomes, Bacterial | 1 | 1997 | 2 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 54 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 43 | 0.030 |
Why?
|
| Ceftazidime | 1 | 1996 | 8 | 0.030 |
Why?
|
| Gloves, Surgical | 1 | 1996 | 7 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 248 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 59 | 0.030 |
Why?
|
| Bacteriuria | 1 | 2015 | 4 | 0.030 |
Why?
|
| Respiration, Artificial | 2 | 2012 | 107 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 14 | 0.030 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1995 | 1 | 0.030 |
Why?
|
| Ticks | 1 | 1995 | 2 | 0.030 |
Why?
|
| Penicillins | 1 | 1995 | 9 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 12 | 0.030 |
Why?
|
| Gastric Juice | 1 | 2015 | 2 | 0.030 |
Why?
|
| Drinking Water | 1 | 2015 | 2 | 0.030 |
Why?
|
| Sputum | 1 | 2015 | 21 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 14 | 0.030 |
Why?
|
| HIV-1 | 1 | 1997 | 234 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1994 | 4 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 34 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 16 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 453 | 0.030 |
Why?
|
| Gentamicins | 1 | 1994 | 20 | 0.030 |
Why?
|
| Campylobacter Infections | 1 | 2014 | 2 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 30 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 22 | 0.030 |
Why?
|
| Chickens | 1 | 2014 | 35 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2014 | 58 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 62 | 0.030 |
Why?
|
| Longevity | 1 | 2014 | 29 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 83 | 0.030 |
Why?
|
| Colistin | 1 | 2013 | 3 | 0.030 |
Why?
|
| Hospitals, Public | 2 | 2007 | 25 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 173 | 0.030 |
Why?
|
| Minocycline | 1 | 2013 | 6 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 111 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 13 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 301 | 0.030 |
Why?
|
| Ventilation | 1 | 2013 | 3 | 0.030 |
Why?
|
| Propensity Score | 1 | 2012 | 31 | 0.020 |
Why?
|
| Nose | 1 | 2013 | 38 | 0.020 |
Why?
|
| Agar | 1 | 2012 | 2 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 254 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2011 | 4 | 0.020 |
Why?
|
| Indiana | 1 | 2011 | 15 | 0.020 |
Why?
|
| Serratia | 1 | 2010 | 5 | 0.020 |
Why?
|
| Florida | 1 | 2010 | 17 | 0.020 |
Why?
|
| Patient Isolation | 1 | 2010 | 14 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 129 | 0.020 |
Why?
|
| APACHE | 2 | 2001 | 27 | 0.020 |
Why?
|
| Drug and Narcotic Control | 1 | 2009 | 3 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 6 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 6 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 18 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 35 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 26 | 0.020 |
Why?
|
| China | 1 | 2009 | 47 | 0.020 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2008 | 2 | 0.020 |
Why?
|
| Porins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Bedding and Linens | 1 | 2007 | 5 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 148 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 63 | 0.020 |
Why?
|
| Methicillin | 1 | 2007 | 7 | 0.020 |
Why?
|
| Gram-Positive Cocci | 1 | 2007 | 4 | 0.020 |
Why?
|
| Alcohols | 1 | 2007 | 7 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 34 | 0.020 |
Why?
|
| Patients | 1 | 2006 | 32 | 0.020 |
Why?
|
| Asphyxia Neonatorum | 1 | 1984 | 1 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1984 | 43 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 84 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 234 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 720 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1984 | 99 | 0.010 |
Why?
|
| Virulence | 1 | 2002 | 8 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 44 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 695 | 0.010 |
Why?
|
| Mortality | 1 | 2002 | 85 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2001 | 103 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1999 | 27 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1998 | 9 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 1998 | 57 | 0.010 |
Why?
|
| Heating | 1 | 1997 | 4 | 0.010 |
Why?
|
| Risk | 1 | 1998 | 202 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 10 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1997 | 17 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 9 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1997 | 18 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 21 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1998 | 91 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 16 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1997 | 56 | 0.010 |
Why?
|
| Monocytes | 1 | 1997 | 57 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 81 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 50 | 0.010 |
Why?
|
| Digestive System | 1 | 1996 | 12 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 123 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 190 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 506 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1995 | 3 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 20 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 144 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 185 | 0.010 |
Why?
|
| Pyruvates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 6 | 0.000 |
Why?
|
| Lactates | 1 | 1984 | 4 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 25 | 0.000 |
Why?
|
| Glucagon | 1 | 1984 | 7 | 0.000 |
Why?
|
| Glycogen | 1 | 1984 | 14 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 89 | 0.000 |
Why?
|
| Liver | 1 | 1984 | 150 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 628 | 0.000 |
Why?
|